FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Walter Loos

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Concepts & Ideas

Procedures

Physiology

Drug Interactions

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Karel Eechoute; Martin N Fransson; Lena E Friberg; Walter J Loos; Ron H J Mathijssen; A K L Reyners; Gaia Schiavon; Alex Sparreboom; Winette T A van der Graaf; Jaap Verweij; Erik A C Wiemer; Floris A de Jong; Ugo De Giorgi
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Anne-Joy M de Graan; Guoqing Du; Laure Elens; Lena E Friberg; Alice A Gibson; Bruno Hagenbuch; Shuiying Hu; Cynthia S Lancaster; Walter J Loos; Ron H J Mathijssen; Torben S Mikkelsen; Amanda Obaidat; Sharyn D Baker; Gitte H Bruun; Thomas J Corydon; Peter de Bruijn; Ron H N van Schaik; Aisha L Walker; Alex Sparreboom
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
L Binkhorst; E de Jonge; Felix E de Jongh; P Hamberg; A Jager; Walter J Loos; I M Ghobadi Moghaddam-Helmantel; Caroline Seynaeve; Teun van Gelder; R H N van Schaik; Jaap Verweij; Ron H J Mathijssen
Effects of CYP induction by rifampicin on tamoxifen exposure.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Walter Loos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Karel Eechoute; Martin N Fransson; Lena E Friberg; Walter J Loos; Ron H J Mathijssen; A K L Reyners; Gaia Schiavon; Alex Sparreboom; Winette T A van der Graaf; Jaap Verweij; Erik A C Wiemer; Floris A de Jong; Ugo De Giorgi
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5780-7.
2012: Anne-Joy M de Graan; Guoqing Du; Laure Elens; Lena E Friberg; Alice A Gibson; Bruno Hagenbuch; Shuiying Hu; Cynthia S Lancaster; Walter J Loos; Ron H J Mathijssen; Torben S Mikkelsen; Amanda Obaidat; Sharyn D Baker; Gitte H Bruun; Thomas J Corydon; Peter de Bruijn; Ron H N van Schaik; Aisha L Walker; Alex Sparreboom
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4433-40.
2012: L Binkhorst; E de Jonge; Felix E de Jongh; P Hamberg; A Jager; Walter J Loos; I M Ghobadi Moghaddam-Helmantel; Caroline Seynaeve; Teun van Gelder; R H N van Schaik; Jaap Verweij; Ron H J Mathijssen
Effects of CYP induction by rifampicin on tamoxifen exposure.
Clinical pharmacology and therapeutics 2012;92(1):62-7.
2012: Gaia Schiavon; Stefan Sleijfer; Jessica van der Bol; Jaap Verweij; Peter de Bruijn; Karel Eechoute; Ron H J Mathijssen; Walter J Loos
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.
Journal of clinical pharmacology 2012;52(7):1115-20.
2012: J A Sprowl; Vanesa Gregorc; C Lazzari; Walter J Loos; Ron H J Mathijssen; Alex Sparreboom
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Clinical pharmacology and therapeutics 2012;91(6):1022-6.
2012: Peter de Bruijn; Anne-Joy M de Graan; Ronald de Wit; Mei-Ho Lam; Ron H J Mathijssen; Annemieke Nieuweboer; Erik A C Wiemer; Walter J Loos
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.
Journal of pharmaceutical and biomedical analysis 2012;59():117-22.
2011: Lisette Binkhorst; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Ron H J Mathijssen; Teun van Gelder; Erik A C Wiemer; Walter J Loos
Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2011;56(5):1016-23.
2011: Ron H J Mathijssen; Walter J Loos; Jaap Verweij
Determining the best dose for the individual patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(33):4345-6.
2011: Anne-Joy M de Graan; Felix E de Jongh; AI de Vos; Filip Y F L de Vos; Walter J Loos; Caroline Seynaeve; Sebastiaan F Teunissen; RJ van Alphen; Bronno van der Holt; Ron H N van Schaik; Jaap Verweij; Jos H Beijnen; Ron H J Mathijssen
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(24):3240-6.
2011: K Eechoute; R M Franke; Walter J Loos; L A Scherkenbach; I Boere; Jaap Verweij; H Gurney; R B Kim; R G Tirona; Ron H J Mathijssen; Alex Sparreboom
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Clinical pharmacology and therapeutics 2011;89(6):816-20.
2011: Inge R H M Konings; Stefan Sleijfer; Ron H J Mathijssen; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Linda M van Dam; Erik A C Wiemer; Jaap Verweij; Walter J Loos
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Cancer chemotherapy and pharmacology 2011;67(5):1055-62.
2011: Jessica van der Bol; Walter J Loos; Floris A de Jong; Esther van Meerten; Inge R H M Konings; Mei H Lam; Peter de Bruijn; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
European journal of cancer (Oxford, England : 1990) 2011;47(6):831-8.
2011: Herman Burger; Walter J Loos; Karel Eechoute; Jaap Verweij; Ron H J Mathijssen; Erik A C Wiemer
Drug transporters of platinum-based anticancer agents and their clinical significance.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2011;14(1):22-34.
2011: Karel Eechoute; Alex Sparreboom; Herman Burger; Ryan M Franke; Gaia Schiavon; Jaap Verweij; Walter J Loos; Erik A C Wiemer; Ron H J Mathijssen
Drug transporters and imatinib treatment: implications for clinical practice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(3):406-15.
2011: Walter J Loos; Anne-Joy M de Graan; Peter de Bruijn; Ron H N van Schaik; Marianne A C van Fessem; Mei-Ho Lam; Ron H J Mathijssen; Erik A C Wiemer
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2011;54(2):387-94.
2011: Frederike K Engels; Walter J Loos; Jessica M van der Bol; Peter de Bruijn; Ron H J Mathijssen; Jaap Verweij; Ron A A Mathot
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(2):353-62.
2011: Jessica M van der Bol; Theo J Visser; Walter J Loos; Floris A de Jong; Erik A C Wiemer; Maarten O van Aken; A S T Planting; Jan H Schellens; Jaap Verweij; Ron H J Mathijssen
Effects of methimazole on the elimination of irinotecan.
Cancer chemotherapy and pharmacology 2011;67(1):231-6.
2010: M J A de Jonge; Marije Slingerland; Walter J Loos; Erik A C Wiemer; Herman Burger; Ron H J Mathijssen; Judith R Kroep; Margret A G den Hollander; Diane van der Biessen; Mei-Ho Lam; Jaap Verweij; Hans Gelderblom
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
European journal of cancer (Oxford, England : 1990) 2010;46(16):3016-21.
2010: Cynthia S Lancaster; Chaoxin Hu; Ryan M Franke; Kelly K Filipski; Shelley J Orwick; Zhaoyuan Chen; Zhili Zuo; Walter J Loos; Alex Sparreboom
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4789-99.
2010: P Hamberg; N Steeghs; Walter J Loos; D van de Biessen; M den Hollander; M Tascilar; Jaap Verweij; Hans Gelderblom; Stefan Sleijfer
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
British journal of cancer 2010;102(12):1699-706.
2010: Peter de Bruijn; Stefan Sleijfer; Mei-Ho Lam; Ron H J Mathijssen; Erik A C Wiemer; Walter J Loos
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2010;51(4):934-41.
2010: Jessica M van der Bol; Ron H J Mathijssen; Geert-Jan M Creemers; A S T Planting; Walter J Loos; Erik A C Wiemer; Lena E Friberg; Jaap Verweij; Alex Sparreboom; Floris A de Jong
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):736-42.
2009: Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Maja J A de Jonge; Thorsten Meyer; Mei-Ho Lam; Jaap Verweij; Erik A C Wiemer; Walter J Loos
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;50(5):977-82.
2009: Constantijne H Mom; Jaap Verweij; Corina N A M Oldenhuis; Jourik A Gietema; Norma Lynn Fox; Renée Miceli; Ferry A L M Eskens; Walter J Loos; Elisabeth G E de Vries; Stefan Sleijfer
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5584-90.
2009: Inge R H M Konings; Frederike K Engels; Stefan Sleijfer; Jaap Verweij; Erik A C Wiemer; Walter J Loos
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
Cancer chemotherapy and pharmacology 2009;64(3):509-16.
2008: Rieneke T Lugtenberg; Karlien Cransberg; Walter J Loos; Anja Wagner; Marielle Alders; Marry M van den Heuvel-Eibrink
Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
Cancer chemotherapy and pharmacology 2008;62(6):1039-44.
2008: Joan B Heijns; M E L van der Burg; Teun van Gelder; Marien W J A Fieren; Peter de Bruijn; Ate van der Gaast; Walter J Loos
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
Cancer chemotherapy and pharmacology 2008;62(5):841-7.
2007: Metin Tascilar; Walter J Loos; Caroline Seynaeve; Jaap Verweij; Stefan Sleijfer
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
The oncologist 2007;12(11):1351-60.
2007: Walter J Loos; William C Zamboni; Frederike K Engels; Peter de Bruijn; M H Lam; R de Wit; Jaap Verweij; Erik A C Wiemer
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
Journal of pharmaceutical and biomedical analysis 2007;45(2):288-94.
2007: Floris A de Jong; Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Ron A A Mathôt; Jos J E M Kitzen; Martin J van den Bent; Jaap Verweij
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer biology & therapy 2007;6(9):1368-74.
2007: Frederike K Engels; Walter J Loos; Ron A A Mathot; Ron van Schaik; Jaap Verweij
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer chemotherapy and pharmacology 2007;60(4):569-79.
2007: Ron H J Mathijssen; Floris A de Jong; Walter J Loos; Jessica van der Bol; Jaap Verweij; Alex Sparreboom
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
2007: Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron van Schaik; M J A de Jonge; A S T Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
2007: Frederike K Engels; Floris A de Jong; Alex Sparreboom; Ron A A Mathot; Walter J Loos; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Ron H J Mathijssen
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
2007: Walter J Loos; Ronald de Wit; Steven J Freedman; Kristien Van Dyck; Jay J Gambale; Susie Li; Gail M Murphy; Connie van Noort; Peter de Bruijn; Jaap Verweij
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 2007;59(3):407-12.
2006: A Felici; Walter J Loos; Jaap Verweij; I Cirillo; Peter de Bruijn; Kees Nooter; Ron H J Mathijssen; M J A de Jonge
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Cancer chemotherapy and pharmacology 2006;58(5):673-80.
2006: Jos J E M Kitzen; Jaap Verweij; Erik A C Wiemer; Walter J Loos
The relevance of microdialysis for clinical on:cology.
Current clinical pharmacology 2006;1(3):255-63.
2006: Floris A de Jong; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Walter J Loos
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer biology & therapy 2006;5(9):1105-10.
2006: Frederike K Engels; Ron A A Mathot; Walter J Loos; Ron van Schaik; Jaap Verweij
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer biology & therapy 2006;5(7):833-9.
2006: Walter J Loos; Felix E de Jongh; Alex Sparreboom; Ronald de Wit; Desirée M van Boven-van Zomeren; Gerrit Stoter; Kees Nooter; Jaap Verweij
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1499-506.
2006: Frederike K Engels; Dirk Buijs; Walter J Loos; Jaap Verweij; Willem H Bakker; Eric P Krenning
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.
Anti-cancer drugs 2006;17(1):63-7.
2005: Alex Sparreboom; Walter J Loos; Herman Burger; Tristan Sissung; Jaap Verweij; William D Figg; Kees Nooter; Hans Gelderblom
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
2005: Charity D Scripture; Janos Szebeni; Walter J Loos; William D Figg; Alex Sparreboom
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
2004: M J A de Jonge; Stan Kaye; Jaap Verweij; C Brock; Sarah Reade; Michelle Scurr; L van Doorn; Coleta Verheij; Walter J Loos; C Brindley; P Mistry; M Cooper; Ian Judson
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
British journal of cancer 2004;91(8):1459-65.
2004: Albert J ten Tije; Walter J Loos; Ming Zhao; Sharyn D Baker; Roelien H Enting; Hans van der Meulen; Jaap Verweij; Alex Sparreboom
Limited cerebrospinal fluid penetration of docetaxel.
Anti-cancer drugs 2004;15(7):715-8.
2004: Frederike K Engels; Albert J ten Tije; Sharyn D Baker; Carlton K K Lee; Walter J Loos; Arnold G Vulto; Jaap Verweij; Alex Sparreboom
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clinical pharmacology and therapeutics 2004;75(5):448-54.
2004: Peter de Bruijn; Edwin W Willems; Walter J Loos; Jaap Verweij; Alex Sparreboom
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Analytical biochemistry 2004;328(1):84-6.
2004: Otto Soepenberg; Alex Sparreboom; M J A de Jonge; A S T Planting; Gerda de Heus; Walter J Loos; C M Hartman; C Bowden; Jaap Verweij
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(5):681-8.
2003: Albert J ten Tije; Walter J Loos; Jaap Verweij; Sharyn D Baker; Kimberly Dinh; William D Figg; Alex Sparreboom
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
2003: Floris A de Jong; Ron H J Mathijssen; Peter de Bruijn; Walter J Loos; Jaap Verweij; Alex Sparreboom
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.
2003: Walter J Loos; Sharyn D Baker; Jaap Verweij; Joke G Boonstra; Alex Sparreboom
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clinical pharmacology and therapeutics 2003;74(4):364-71.
2003: Hans Gelderblom; Walter J Loos; Alex Sparreboom; Otto Soepenberg; M J A de Jonge; Desirée M van Boven-van Zomeren; Jaap Verweij
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1542-6.
2003: Walter J Loos; Hans Gelderblom; Jaap Verweij; Desirée M van Boven-van Zomeren; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Anti-cancer drugs 2003;14(3):227-32.
2003: Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clinical pharmacokinetics 2003;42(7):665-85.
2002: Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Walter J Loos; Alex Sparreboom
Effects of St. John's wort on irinotecan metabolism.
Journal of the National Cancer Institute 2002;94(16):1247-9.
2002: Walter J Loos; Janos Szebeni; Albert J ten Tije; Jaap Verweij; Desirée M van Zomeren; Kyu-nung Chung; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Anti-cancer drugs 2002;13(7):767-75.
2002: Ron H J Mathijssen; Jaap Verweij; Walter J Loos; Peter de Bruijn; Kees Nooter; Alex Sparreboom
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
British journal of cancer 2002;87(2):144-50.
2002: Ron H J Mathijssen; Walter J Loos; Jaap Verweij; Alex Sparreboom
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Current cancer drug targets 2002;2(2):103-23.
2002: Walter J Loos; Jaap Verweij; Diederik F S Kehrer; Peter de Bruijn; Franciscus M H de Groot; Marta Hamilton; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):856-62.
2002: M Louwerens; Carolien H Smorenburg; Alex Sparreboom; Walter J Loos; Jaap Verweij; Ronald de Wit
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(4):497-504.
2002: Diederik F S Kehrer; Annelies M Bos; Jaap Verweij; Harry J Groen; Walter J Loos; Alex Sparreboom; M J A de Jonge; Marta Hamilton; Terri Cameron; Elisabeth G E de Vries
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1222-31.
2002: J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; Per Dombernowsky; Robert Paridaens; A T van Oosterom; Jaap Verweij; Walter J Loos; Hilary Calvert; Nicholas Pavlidis; H Cortes-Funes; Jantien Wanders; MW Roelvink; Cristiana Sessa; K Selinger; Paul Wissel; Teresa Gamucci; Axel R Hanauske
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
2002: Walter J Loos; Desirée M van Zomeren; Hans Gelderblom; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(1):99-105.
2002: Hans Gelderblom; Walter J Loos; Jaap Verweij; M E L van der Burg; M J A de Jonge; E Brouwer; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):205-13.
2001: Hans Gelderblom; Alex Sparreboom; M J A de Jonge; Walter J Loos; E Wilms; Marijke Mantel; B Hennis; I Camlett; Jaap Verweij; M E L van der Burg
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
British journal of cancer 2001;85(8):1124-9.
2001: Felix E de Jongh; Jaap Verweij; Walter J Loos; Ronald de Wit; M J A de Jonge; A S T Planting; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3733-9.
2001: Ron H J Mathijssen; RJ van Alphen; Jaap Verweij; Walter J Loos; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2182-94.
2001: J H M Schellens; Per Dombernowsky; J Cassidy; R Epelbaum; L Dirix; E H Cox; Jantien Wanders; F Calabresi; Robert Paridaens; S Monfardini; J Wolff; Walter J Loos; Jaap Verweij; Nicholas Pavlidis; Axel R Hanauske
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Anti-cancer drugs 2001;12(7):583-90.
2001: Diederik F S Kehrer; Otto Soepenberg; Walter J Loos; Jaap Verweij; Alex Sparreboom
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anti-cancer drugs 2001;12(2):89-105.
2000: Walter J Loos; H J Gelderblom; Jaap Verweij; E Brouwer; M J A de Jonge; Alex Sparreboom
Gender-dependent pharmacokinetics of topotecan in adult patients.
Anti-cancer drugs 2000;11(9):673-80.
2000: E Brouwer; Jaap Verweij; Peter de Bruijn; Walter J Loos; M Pillay; Dirk Buijs; Alex Sparreboom
Measurement of fraction unbound paclitaxel in human plasma.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1141-5.
2000: A J Gelderblom; Walter J Loos; M J A de Jonge; Alex Sparreboom; A S T Planting; M E L van der Burg; E Brouwer; Coleta Verheij; L Ouwens; Solange Hearn; Jaap Verweij
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1205-7.
2000: Walter J Loos; Hans Gelderblom; Alex Sparreboom; Jaap Verweij; M J A de Jonge
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2685-9.
2000: Lia van Zuylen; Luca Gianni; Jaap Verweij; Klaus Mross; E Brouwer; Walter J Loos; Alex Sparreboom
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Anti-cancer drugs 2000;11(5):331-7.
2000: Walter J Loos; Peter de Bruijn; Jaap Verweij; Alex Sparreboom
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs 2000;11(5):315-24.
2000: M J A de Jonge; Walter J Loos; Hans Gelderblom; A S T Planting; M E L van der Burg; Alex Sparreboom; E Brouwer; V van Beurden; Marijke Mantel; E Doyle; Solange Hearn; G Ross; Jaap Verweij
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2104-15.
2000: Hans Gelderblom; Walter J Loos; Jaap Verweij; M J A de Jonge; Alex Sparreboom
Topotecan lacks third space sequestration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1288-92.
2000: Walter J Loos; Diederik F S Kehrer; E Brouwer; Jaap Verweij; Peter de Bruijn; Marta Hamilton; S Gill; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(1):155-63.
1999: Walter J Loos; Peter de Bruijn; Lia van Zuylen; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):293-7.
1999: Alex Sparreboom; Walter J Loos; Kees Nooter; Gerrit Stoter; Jaap Verweij
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(1):111-9.
1999: Alex Sparreboom; A S T Planting; Roxanne C Jewell; M E L van der Burg; Ate van der Gaast; Peter de Bruijn; Walter J Loos; Kees Nooter; L H Chandler; Elaine M Paul; Paul Wissel; Jaap Verweij
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Anti-cancer drugs 1999;10(8):719-28.
1999: Walter J Loos; Jaap Verweij; H J Gelderblom; M J A de Jonge; E Brouwer; BK Dallaire; Alex Sparreboom
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.
Anti-cancer drugs 1999;10(8):705-10.
1999: M J A de Jonge; Cornelis J A Punt; A H Gelderblom; Walter J Loos; V van Beurden; A S T Planting; M E L van der Burg; Lydia Van Maanen; BK Dallaire; Jaap Verweij; D J Wagener; Alex Sparreboom
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2219-26.
1999: Alex Sparreboom; M J A de Jonge; C J Punt; Walter J Loos; Kees Nooter; Gerrit Stoter; M G Porro; Jaap Verweij
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):816-20.
1999: M J A de Jonge; Jaap Verweij; Walter J Loos; BK Dallaire; Alex Sparreboom
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacology and therapeutics 1999;65(5):491-9.
1999: Lia van Zuylen; J H M Schellens; Swan Hoo Goey; LC Pronk; MM de Boer-Dennert; Walter J Loos; J Ma; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
1999: Alex Sparreboom; Lia van Zuylen; E Brouwer; Walter J Loos; Peter de Bruijn; Hans Gelderblom; M Pillay; Kees Nooter; Gerrit Stoter; Jaap Verweij
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Cancer research 1999;59(7):1454-7.
1999: Peter de Bruijn; Jaap Verweij; Walter J Loos; HJ Kolker; A S T Planting; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
Analytical biochemistry 1999;266(2):216-21.
1999: Ron H J Mathijssen; RJ van Alphen; M J A de Jonge; Jaap Verweij; Peter de Bruijn; Walter J Loos; Kees Nooter; Laurent Vernillet; Gerrit Stoter; Alex Sparreboom
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Anti-cancer drugs 1999;10(1):9-16.
1999: C J H Gerrits; J H M Schellens; Howard A Burris; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; Daniel Von Hoff; Jaap Verweij
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1998: Alex Sparreboom; M J A de Jonge; Peter de Bruijn; E Brouwer; Kees Nooter; Walter J Loos; RJ van Alphen; Ron H J Mathijssen; Gerrit Stoter; Jaap Verweij
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2747-54.
1998: Alex Sparreboom; Peter de Bruijn; M J A de Jonge; Walter J Loos; Gerrit Stoter; Jaap Verweij; Kees Nooter
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):225-35.
1998: Alex Sparreboom; Jaap Verweij; M E L van der Burg; Walter J Loos; E Brouwer; L Viganò; A Locatelli; AI de Vos; Kees Nooter; Gerrit Stoter; Luca Gianni
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1937-42.
1998: Alex Sparreboom; M J A de Jonge; Cornelis J A Punt; Kees Nooter; Walter J Loos; M G Porro; Jaap Verweij
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1915-9.
1998: E Brouwer; Jaap Verweij; B Hauns; Walter J Loos; Kees Nooter; Klaus Mross; Gerrit Stoter; Alex Sparreboom
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Analytical biochemistry 1998;261(2):198-202.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; A S T Planting; M E van den Burg; Gladys I Rodriguez; V van Beurden; Walter J Loos; IR Hudson; S Fields; Jaap Verweij; Daniel Von Hoff
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: J Ma; M Maliepaard; Kees Nooter; Walter J Loos; HJ Kolker; Jaap Verweij; Gerrit Stoter; J H M Schellens
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
British journal of cancer 1998;77(10):1645-52.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; S Fields; Daniel Von Hoff; Jaap Verweij
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Alex Sparreboom; Peter de Bruijn; Kees Nooter; Walter J Loos; Gerrit Stoter; Jaap Verweij
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):159-64.
1998: Alex Sparreboom; Walter J Loos; Jaap Verweij; AI de Vos; M E L van der Burg; Gerrit Stoter; Kees Nooter
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Analytical biochemistry 1998;255(2):171-5.
1997: AI de Vos; Kees Nooter; Jaap Verweij; Walter J Loos; E Brouwer; Peter de Bruijn; E J Ruijgrok; M E L van der Burg; Gerrit Stoter; Alex Sparreboom
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1145-50.
1997: Peter de Bruijn; Jaap Verweij; Walter J Loos; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):277-85.
1997: Walter J Loos; Alex Sparreboom; Jaap Verweij; Kees Nooter; Gerrit Stoter; J H M Schellens
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
1997: Walter J Loos; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(2):437-41.
1997: Geert-Jan Creemers; C J H Gerrits; John R Eckardt; J H M Schellens; Howard A Burris; A S T Planting; Gladys I Rodriguez; Walter J Loos; IR Hudson; C Broom; Jaap Verweij; Daniel Von Hoff
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: J H M Schellens; W Van de Vrie; Walter J Loos; HJ Kolker; Jaap Verweij; Gerrit Stoter; N M Durante; A M Eggermont
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
Cancer chemotherapy and pharmacology 1997;41(1):48-52.
1996: Geert-Jan Creemers; C J H Gerrits; J H M Schellens; A S T Planting; M E L van der Burg; V van Beurden; MM de Boer-Dennert; M Harteveld; Walter J Loos; IR Hudson; Gerrit Stoter; Jaap Verweij
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
1996: Walter J Loos; Gerrit Stoter; Jaap Verweij; J H M Schellens
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Journal of chromatography. B, Biomedical applications 1996;678(2):309-15.
1996: J Ma; Jaap Verweij; A S T Planting; HJ Kolker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; Gerrit Stoter; J H M Schellens
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
1994: J H M Schellens; A S T Planting; B A van Acker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; I Koier; R T Krediet; G Stoter; Jaap Verweij
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
1993: J H M Schellens; Walter J Loos; Jos H Beijnen; G Stoter; Jaap Verweij
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.